Emily vs HSE Over Life-Saving Drug | Belfast News

A 28-year-old trainee solicitor, Emily Felix, is suing the Health Service Executive over a devastating delay in accessing Skyclarys, the first drug approved to treat her rare, progressive neurological disease Friedreich’s Ataxia. With only 200 people in Ireland affected, Emily’s condition is rapidly worsening—impacting her mobility, speech, and mental health—and she’s demanding the HSE stop dragging its feet. Her legal team argues the HSE prioritized cost talks over patient care, violating her constitutional right to life. The High Court has granted her permission to challenge the HSE, following a prior rejection of her Treatment Abroad Scheme application. The case, set for a September 10th hearing, could set a precedent for how Ireland handles life-saving drug approvals for ultra-rare diseases. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/49f0dded91ce6225